Maraviroc – A CCR5 Antagonist for the Treatment of HIV-1 Infection

por Van Der Ryst, Elna
Publicado 2015

An exploratory survey measuring stigma and discrimination experienced by people living with HIV/AIDS in South Africa: the People Living with HIV Stigma Index

por dos Santos, Monika ML, Kruger, Pieter, Mellors, Shaun E, Wolvaardt, Gustaaf, van der Ryst, Elna
Publicado 2014

Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials

por Jubb, Becky, Lewis, Marilyn, McFadyen, Lynn, Simpson, Paul, Mori, Julie, Chan, Phylinda, Weatherley, Barry, van der Ryst, Elna, Westby, Mike, Craig, Charles
Publicado 2019

Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings

por Cooper, David A., Heera, Jayvant, Ive, Prudence, Botes, Mariette, Dejesus, Edwin, Burnside, Robert, Clumeck, Nathan, Walmsley, Sharon, Lazzarin, Adriano, Mukwaya, Geoffrey, Saag, Michael, van Der Ryst, Elna
Publicado 2014

Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized,...

por Lewis, Marilyn, Mori, Julie, Toma, Jonathan, Mosley, Mike, Huang, Wei, Simpson, Paul, Mansfield, Roy, Craig, Charles, van der Ryst, Elna, Robertson, David L., Whitcomb, Jeannette M., Westby, Mike
Publicado 2018

Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1

por Giaquinto, Carlo, Mawela, Muthuhadini Patience, Chokephaibulkit, Kulkanya, Negra, Marinella Della, Mitha, Ismail Haroon, Fourie, Jan, Fang, Annie, van der Ryst, Elna, Valluri, Srinivas Rao, Vourvahis, Manoli, Zhang-Roper, Rebecca Yanhui, Craig, Charles, McFadyen, Lynn, Clark, Andrew, Heera, Jayvant
Publicado 2018